Program: Special-Interest Sessions
Hematology Disease Topics & Pathways:
Iron Deficiency, Clinical Practice (Health Services and Quality), Diversity, Equity, and Inclusion (DEI), Hemoglobinopathies, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Metabolic Disorders
Hematology Disease Topics & Pathways:
Iron Deficiency, Clinical Practice (Health Services and Quality), Diversity, Equity, and Inclusion (DEI), Hemoglobinopathies, Diseases, Lymphoid Malignancies, Myeloid Malignancies, Metabolic Disorders
Saturday, December 7, 2024: 2:00 PM-3:30 PM
Room 11
(San Diego Convention Center)
Co-chairs:
Angela C Weyand, MD, University of Michigan
and
Adam Cuker, MD, MS, University of Pennsylvania
Disclosures:
Weyand: Genentech: Honoraria; Bayer: Honoraria; Novo Nordisk: Honoraria, Research Funding; Biomarin: Honoraria; Octapharma: Honoraria; Pfizer: Research Funding; Takeda: Consultancy, Honoraria, Research Funding; Hemab: Consultancy; Sanofi: Consultancy, Honoraria, Research Funding. Cuker: Bioverativ, MingSight Pharmaceuticals, Pfizer, Sanofi, Stago, Synergy: Consultancy; Alexion, Bayer, Bioverativ, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda: Research Funding.
This year's Quality Symposium will focus on practical strategies for combatting healthcare disparities. First, Dr. Melissa Creary will discuss the Michigan Social Health Interventions to Eliminate Disparities (MSHIELD) program, a statewide data-driven, community-partnered, and equity-centered quality improvement effort. Then Dr. Michelle Sholzberg will review the development and impact of the "Raise the Bar" project, which aims to eliminate disparities in the recognition and management of iron deficiency by adjusting reference ranges. The session will conclude with a talk by Dr. Thomas Greg Knight on mitigating the impact of financial toxicity in patients with hematologic malignancies.
See more of: Special-Interest Sessions